Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Starlinger

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2025
The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLMVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Annals of Surgical Oncology|February 6, 2024
Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic AdenocarcinomaAlessandro Fogliati, Andrea Zironda, Guido Fiorentini, et al.
JCI Insight|June 28, 2022
SHP2 inhibition enhances Yes-associated protein-mediated liver regeneration in murine partial hepatectomy modelsRyan D Watkins, EeeLN H Buckarma, Jennifer L Tomlinson, et al.
Hepatology (Baltimore, Md.)|July 7, 2025
Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinomaYawen Dong, Zhihao Li, Vanja Podrascanin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancerYawen Dong, David Pereyra, Vanja Podrascanin, et al.
Annals of Surgical Oncology|January 27, 2026
ASO Visual Abstract: The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases-A Retrospective Single-Center AnalysisVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 3, 2025
Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure-A multivariable model with APRI+ALBIYawen Dong, Lindsey A Gregory, Vanja Podrascanin, et al.
Annals of Surgical Oncology|December 19, 2025
The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center AnalysisVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2025
The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLMVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Annals of Surgical Oncology|February 6, 2024
Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic AdenocarcinomaAlessandro Fogliati, Andrea Zironda, Guido Fiorentini, et al.
JCI Insight|June 28, 2022
SHP2 inhibition enhances Yes-associated protein-mediated liver regeneration in murine partial hepatectomy modelsRyan D Watkins, EeeLN H Buckarma, Jennifer L Tomlinson, et al.
Hepatology (Baltimore, Md.)|July 7, 2025
Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinomaYawen Dong, Zhihao Li, Vanja Podrascanin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancerYawen Dong, David Pereyra, Vanja Podrascanin, et al.
Annals of Surgical Oncology|January 27, 2026
ASO Visual Abstract: The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases-A Retrospective Single-Center AnalysisVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 3, 2025
Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure-A multivariable model with APRI+ALBIYawen Dong, Lindsey A Gregory, Vanja Podrascanin, et al.
Annals of Surgical Oncology|December 19, 2025
The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center AnalysisVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Pageof 12